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Congenital myasthenic syndromes are a group of rare and genetically heterogenous disorders resulting from defects in the structure
and function of the neuromuscular junction. Patients with congenital myasthenic syndrome exhibit fatigable muscle weakness with
a variety of accompanying phenotypes depending on the protein affected. A cohort of patients with a clinical diagnosis of con-
genital myasthenic syndrome that lacked a genetic diagnosis underwent whole exome sequencing in order to identify genetic
causation. Missense biallelic mutations in the MYO9A gene, encoding an unconventional myosin, were identified in two unrelated
families. Depletion of MYO9A in NSC-34 cells revealed a direct effect of MYO9A on neuronal branching and axon guidance.
Morpholino-mediated knockdown of the two MYO9A orthologues in zebrafish, myo9aa/ab, demonstrated a requirement for
MYO9A in the formation of the neuromuscular junction during development. The morphants displayed shortened and abnormally
branched motor axons, lack of movement within the chorion and abnormal swimming in response to tactile stimulation. We
therefore conclude that MYO9A deficiency may affect the presynaptic motor axon, manifesting in congenital myasthenic syn-
drome. These results highlight the involvement of unconventional myosins in motor axon functionality, as well as the need to look
outside traditional neuromuscular junction-specific proteins for further congenital myasthenic syndrome candidate genes.
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Introduction
The vertebrate neuromuscular junction (NMJ) is a highly
specialized cholinergic synapse, critical for the initiation of
nerve-evoked muscle contractions by means of signal trans-
mission from the presynaptic motor axons to the postsy-
naptic muscle fibres. Due to the highly organized and
structured nature of the NMJ, loss or dysregulation of
one of a number of proteins can affect synaptic function
leading to congenital myasthenic syndrome (CMS), a group
of rare, genetically heterogeneous disorders (Cruz et al.,
2014). CMS is characterized by fatigable muscle weakness,
commonly affecting facial muscles, including muscles that
control the eyelids and move the eyes, as well as those
involved in chewing and swallowing. However, diagnosis
of CMS is only confirmed upon detection of abnormal jitter
on single fibre EMG and/or decrement in repetitive nerve
stimulation, indicating dysfunction of the NMJ transmis-
sion. To date, in excess of 20 causative genes have been
reported for CMS. These only rarely affect the pre-synaptic
NMJ, such as choline acetyltransferase mutations, or the
synaptic cleft, by disrupting COLQ, but mainly affect pro-
teins of the post-synaptic NMJ, including the subunits of
acetylcholine receptors (Cruz et al., 2014). Despite the
number of genes identified, 20% of individuals with a
clinical diagnosis of CMS are lacking a genetic diagnosis,
indicating that there are still a number of causative genes to
be identified (Finlayson et al., 2013).
The use of whole-exome sequencing to identify novel
causative variants and genes remains an invaluable
method for the successful diagnosis and treatment of
these individuals. Here, we have identified compound het-
erozygous and homozygous variants in an unconventional
myosin gene, MYO9A in two unrelated CMS families.
Unconventional myosins form a subset of the myosin
family of molecular motors that have the ability to bind
to actin filaments and move relative to the actin cytoskel-
eton of cells. They are expressed in neurons of the periph-
eral nervous system, and have been shown to play an
important role in axonal transport (Bridgman, 2009).
Unconventional myosins are composed of three distinct re-
gions: the head region, which is able to bind actin fila-
ments, hydrolyse ATP and generate force; the neck
region, which contains a varying number of IQ motifs for
the binding of light chains such as calmodulin; and the tail
region, which is highly divergent, conveying functions spe-
cific to each class (Hartman et al., 2011). Thus far uncon-
ventional myosins have been associated with Usher
syndrome (mutations in MYO7A) (Well et al., 1995) and
Griscelli syndrome (mutations in MYO5A) (Pastural et al.,
1997). MYO9A maintains the features of typical myosins
including the myosin motor domain (Fig. 1A); however, it
acts as a single headed processive motor and has a tail
region containing a Rho-GTPase domain, through which
MYO9A can inhibit RHOA by stimulating its GTPase ac-
tivity (Liao et al., 2010). Following the identification of
mutations in the MYO9A gene in three patients with
CMS, analysis of MYO9A localization and function
in vitro and in vivo offers preliminary evidence for a role
of the protein at the NMJ.
Materials and methods
Patients
Patient 1 is the first daughter of healthy non-consanguineous
parents of German origin (Fig. 1B). She was referred to paedi-
atric neurology due to swallowing difficulties, proximal and
Figure 1 Structure of MYO9A and patient pedigrees. (A) Diagram depicting the structure of MYO9A and the protein position of the
variants identified in Patients 1–3. Sequences before and after the Rho-GTPase domain are predicted to adopt a coiled coil structure (Gorman
et al., 1999), represented by orange boxes. Accession number: NM_006901, Transcript: ENST00000356056. (B) Pedigree for Patient 1. (C)
Pedigree for Patients 2 and 3. (D) Image of Patients 2 and 3 displaying bilateral ptosis and ophthalmoplegia; with asymmetric upward deviation of
gaze (left eye) in the male patient.
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distal muscle weakness, episodic apnoea, respiratory failure
and ptosis, all with neonatal onset. The patient was aged 4
years at last examination and remains dependant on feeding
through a percutaneous endoscopic gastrostromy. A diagnosis
of CMS was made following the finding of an abnormal jitter
on the orbicularis oculi with single fibre EMG; four abnormal
pairs were recorded at an average jitter of 75 ms. At a different
site of the orbicularis oculi unstable potentials were identified,
even when the stimulation intensity was increased. Testing was
then ceased due to distress of the infant; however, results are
fully compatible with CMS. With concentric needle EMG there
was no evidence of active denervation and the motor unit
action potentials had normal configuration making reinnerva-
tion as an alternative explanation for abnormal jitter very un-
likely. Brain MRI did not reveal any pathological findings and
metabolic tests including creatine kinase, organic acids in
urine, amino acids in serum and acylcarnitines in blood were
all normal. While not yet objectively tested, cognitive function
may be slightly delayed. The patient responds positively to a
combination of pyridostigmine and 3,4-DAP, showing marked
improvements in motor and respiratory function.
Two Kurdish siblings (Fig. 1C), Patients 2 and 3, had pre-
natal onset of symptoms with reduced foetal movements. At
birth Patient 2, who was 5 years of age at last examination,
presented with bilateral ptosis and after 2 months showed
generalized hypotonia and difficulty with swallowing and
chewing. Head control was obtained at 12 months, sitting at
3 years, and walking with support at 5 years of age.
Symmetric multivectorial nystagmus, left eye upgaze deviation
and ophthalmoplegia are also present (Fig. 1D). Respiratory
crises have occurred following oral intake of 3.4-DAP and
fluoxetine, as well as during respiratory infection. Patient 2
has also presented with learning difficulties, and has not yet
developed the ability to speak. Patient 3, who was 11 years of
age at last examination, presented with bilateral ptosis within
the first week following birth and in the subsequent few
months developed generalized hypotonia, absence of head
and truncal control, and difficulty with swallowing and chew-
ing. Sitting was achieved at 12 months, head control at 18
months, and the ability to walk unassisted at 30 months of
age. Nystagmus (usually vertical) and oculomotor apraxia with
head tilt and symmetric ophthalmoplegia are also present.
Episodes of respiratory crises occur during respiratory infec-
tion. Brain MRI did not show any pathology. Metabolic test-
ing was normal, including tandem mass spectrometry and
creatine kinase in serum, organic acids in urine and amino
acids in serum. The diagnosis of CMS was made following
the finding of an increased jitter on single fibre EMG in the
younger sibling, and a 22% decrement on repetitive nerve
stimulation to the right ala nasi muscle in the older sibling.
Both patients showed improvement in ptosis, swallowing,
chewing and breathing in response to pyridostigmine treat-
ment. The unaffected parents are consanguineous and have
previously lost four children during the first year of life, all
with respiratory failure, feeding difficulties and hypotonia.
Consent for research was obtained by the referring
physicians.
Whole-exome sequencing
Whole-exome sequencing was carried out by deCODE Genetics
(Iceland) for Patient 1 and both parents, as well as Patients 2
and 3 and their mother. Exome capture was performed with the
62Mb Nextera Rapid Capture Expanded Exome kit (Illumina)
and sequenced on an Illumina HiSeq 2500 platform. Reads
were aligned to the hg19 reference genome using BWA and
variants called using GATK. Data for each patient were made
available through deCODE’s proprietary platform (Clinical
Sequence Analyser). Data were then filtered to include only
low frequency coding variants present in 41% of the control
population, ExAC database (http://exac.broadinstitute.org/), and
compatible with an autosomal recessive mode of inheritance as
this fits with both pedigrees analysed. Sporadic inheritance was
also considered for Patient 1. Only mutations causing moderate
[missense and in-frame indels (insertions/deletions)] and high
impact (nonsense, frameshifting indels and essential splice
sites) effects on the protein structure were included in analysis.
Variants were also excluded by manual filtering, including ana-
lysis of read depth, alignment of reads and quality of variants
by visual inspection. Variants that remained were subjected to
segregation analysis using family DNA.
Cell culture
NSC-34 cells were cultured to sub-confluence in Dulbecco’s
modified Eagle medium (DMEM; Life Technologies) supple-
mented with 10% foetal bovine serum and 100 units/ml peni-
cillin/streptomycin.
Short hairpin RNA knockdown in
NSC-34 cells
Short hairpin (sh)RNA sequences targeting the mouse Myo9a
gene were designed using the BLOCK-iTTM RNAi Designer
(Life Technologies) and cloned into the pSuperior vector
(Supplementary Fig. 1). Following transfection, cells were se-
lected using puromycin at 3 mg/ml and cultured for 14 days to
confirm stable transfection.
Quantitative real time polymerase
chain reaction
To confirm the shRNA-mediated knockdown of Myo9a from
NSC-34 cells, total RNA from knockdown and control NSC-
34 cells was isolated using TRIzol Reagent (Life
Technologies). cDNA was synthesized from isolated RNA by
incubation with random primers and SuperScript III Reverse
Transcriptase (Life Technologies) for 2 h at 37C. Quantitative
reverse transcription polymerase chain reaction (qRT-PCR)
was performed using a SYBR Green JumpStartTM Taq
ReadyMix according to manufacturer’s instructions (Sigma
S4438), with primers listed in Supplementary Table 2.
Beta-actin was used as an endogenous control, as used else-
where (Ryan et al., 2009). Three biological replicates in trip-
licate were run for Myo9a and Actb (beta-actin), with a
corresponding no template control. The relative expression
ratio (RER) was determined using the formula:
RER ofMyo9a ¼ 2
CttargetðKDcontrolÞ
2CtrefðKDcontrolÞ
where Ct is the difference in crossing points, ref is the cor-
responding value for the reference gene (Actb) and KD refers
to the knockdown cells.
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Immunofluorescent staining of whole
mouse muscle and cells
Mouse lumbrical muscles and NSC-34 cells were fixed in par-
aformaldehyde (1% and 4%, respectively). Tissue and cells were
then permeabilized in 0.1% TritonTM X-100 in PBS, followed
by incubation in 4% bovine serum albumin (BSA) in phosphate-
buffered saline (PBS) at room temperature. Primary antibodies
used are: mouse monoclonal anti-Myosin IXA (1:500, ab76683,
Abcam) and rabbit polyclonal anti-synaptophysin (1:100, Fisher
Scientific). Secondary antibodies applied are: Alexa Fluor 488
goat anti-mouse (1:500, Life Technologies), Alexa Fluor 350
goat anti-rabbit (1:2000, Life Technologies) and Alexa Fluor
594 goat anti-mouse (1:500, Life Technologies). Direct antibo-
dies used include Alexa Fluor 594 -bungarotoxin conjugate
(1:1000, Life Technologies) and Oregon Green 488 phalloidin
(1:1000, Life Technologies). All antibodies were diluted in 4%
BSA in PBS, and washes carried out using PBS, except for -
bungarotoxin, which was diluted in Lilies solution (12mM
NaHCO3, 4mM KCl, 1mM KH2PO4, 138.8mM NaCl,
1mM MgCl2, 2mM CaCl2, 11mM glucose). Samples were
mounted in Vectashield (Vector Laboratories).
Morpholino knockdown in zebrafish
embryos
Interrogation of the UCSC database (Kent et al., 2002; http://
genome.ucsc.edu/) revealed two orthologues of MYO9A in zeb-
rafish, myo9aa and myo9ab (ZV9/danRer7 assembly). An anti-
sense morpholino oligonucleotide targeting the splice donor site
of exon 4 myo9aa and the splice donor site of exon 7 myo9ab
were designed and synthesized by Gene Tools LLC (USA). A
p53 morpholino oligonucleotide was also purchased and a mor-
pholino oligonucleotide against a human beta-globin mutation
was used as a negative control. Sequences are provided in
Supplementary Table 1. Knockdown was performed in zygotes
of the golden strain (genotype slc24a5b1/+ ) of zebrafish
[Zebrafish International Resource Centre (ZIRC)] and Tg(islet-
1:GFP) zebrafish (Higashijima et al., 2000). Morpholino oligo-
nucleotide preparation and injection procedure are described in
the Supplementary material. At 48 hours post-fertilization (hpf)
zebrafish were stimulated on the head or tail with a fine pipette
tip to provoke a touch-evoked swim response.
Immunofluorescent staining of whole
mount zebrafish
At 48 hpf, injected embryos were dechorionated with Pronase
E (Sigma Aldrich) and euthanized by anaesthetic overdose.
Whole mount immunofluorescent staining of zebrafish was
performed as described previously (Muller et al., 2010). The
NMJs were visualized with a mouse anti-SV2 antibody (1:200,
Developmental Studies Hybridoma Bank) and Alexa Fluor
594 -bungarotoxin conjugate (1:1000, Life Technologies).
Reverse transcription polymerase
chain reaction
Total RNA was isolated from 30–40 myo9aa/myo9ab morpho-
lino oligonucleotide-injected and non-injected zebrafish embryos
at 48 hpf using TRIzol Reagent (Life Technologies) and cDNA
synthesized by incubation with Random Primers (Promega) and
dNTPs at 65C for 5min, followed by incubation with
RNaseOUTTM Recombinant Ribonuclease Inhibitor (Life
Technologies) and SuperScript III Reverse Transcriptase (Life
Technologies) according to the manufacturer’s instructions.
PCR was then performed using the primers listed in
Supplementary Table 2.
Microscopy and image analysis
Cells were visualized using an Axio Imager Z1 fluorescent
microscope. Whole mouse muscle, knockdown cells and zebra-
fish were visualized using a Nikon A1R laser scanning con-
focal microscope. Z-stack images of the zebrafish were
obtained by scanning one-half of the myotome of the trunk.
NSC-34 cells were imaged with a Nikon eclipse TS100 micro-
scope for branch analysis. Images taken with the confocal and
Nikon eclipse microscopes were analysed using the NIS-elem-
ents AR 4.20.02 software, including NSC-34 cell branching
counts and neurite length measurements. Neurites 420 mm
length were included in analysis. Islet-1 and golden strain zeb-
rafish were imaged live with a Leica MZ 16 Fluorescent micro-
scope at with an 8 or 4 objective, respectively, and at 24
hpf the number of tail movements within the chorion of the
injected and control embryos was assessed in 10 s using a
Leica stereomicroscope with a Chameleon digital camera
(CMLN-13s2M).
Statistical analysis
The two-sample t-test was used to compare the quantity and
length of control knockdown and MYO9A knockdown NSC-
34 cell neurites, as well as the number of spontaneous move-
ments performed by zebrafish in the chorion at 24 hpf.
P5 0.05 was taken as statistically significant.
Results
Exome sequencing
Analysis of whole-exome sequencing data for Patient 1
and both of her unaffected parents was carried out and
the number of variants identified at each stage of the
workflow is shown in Table 1. Segregation analysis by
Sanger sequencing of her unaffected sister allowed the ex-
clusion of TNXB, leaving only two genes with compound
heterozygous variants co-segregating with the disease:
MYO9A (Fig. 1A) and AKAP11. AKAP11 encodes an A
kinase anchor protein, expressed at high levels in sperm-
atogenesis and mature sperm where it is hypothesized to
be involved in cell cycle control (Pruitt et al., 2014).
MYO9A encodes an unconventional myosin protein,
part of a family of molecular motors in which members
have previously been associated with neuronal growth,
and MYO9A in particular with cell migration (Suter
et al., 2000; Zhu et al., 2007; Omelchenko, 2012).
Although it cannot be ruled out completely, it would
seem highly unlikely that mutant AKAP11 causes CMS.
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MYO9A was therefore prioritized as the best candidate
based on expression in muscle and nerve, and a function
that could be consistent with causing CMS.
The MYO9A variants cause missense changes in highly
conserved regions of the protein: one variant
(rs149046541) is in exon 25 of the main transcript,
which results in p.R1517H, and has a minor allele fre-
quency (MAF) of 0.09% in the ExAC database. The
other is in exon 40, rs142345927, which results in
p.R2283H with a MAF of 0.2% in the ExAC database.
The variants both reside in the tail domain: p.R1517H is
located in a coiled coil region between an IQ motif and a
protein kinase c domain and p.R2283H is located towards
the N-terminus, adjacent to the Rho-GTPase domain
(Fig. 1A). Both variants are predicted to be damaging by
in silico variant effect prediction software (Schwarz et al.,
2014). Screening of whole-exome sequencing data from
277 patients, 50 of whom had a clinical diagnosis of
CMS, identified another variant in MYO9A in CMS
Patients 2 and 3 that segregates with the disease. The
variant, rs150726107, which results in p.D1698G, has a
MAF of 0.06% in the ExAC database. This variant is
homozygous in this sib-pair, with parents both heterozy-
gous for the variant as confirmed by Sanger sequencing.
p.D1698G substitutes a highly conserved aspartic acid
residue for glycine, again in the region between the IQ
motif and the protein kinase C domain of the tail.
Splicing prediction algorithms also indicate that this vari-
ant may introduce a new splice site or alter a splice en-
hancer site (Desmet et al., 2009).
Remaining variants that co-segregate with the disease in
Patients 2 and 3 are shown in Table 1. Variants in
MAP3K8, ADAMTSL3, ZNF862, ZNF655 and
CHRNB4 were excluded based on functions unrelated to
CMS following a literature search. Mutations in RYR1 are
associated with malignant hyperthermia and congenital
myopathies (Snoeck et al., 2015). The variant identified
in CSPP1 has previously been reported in a patient with
Joubert syndrome; however, we believe that the phenotype
of our patients is not consistent with this disorder, includ-
ing the defining feature of vermis cerebellar hypoplasia,
lack of seizures and other CNS or cerebellar ataxia symp-
toms (Tuz et al., 2014). In addition, MYO9A is the
only gene shared between the two unrelated families
with mutations that conform to the predefined filtering
criteria.
MYO9A is expressed at the neuro-
muscular junction in mouse
To assess whether MYO9A is expressed at the NMJ in
mammals we stained mouse lumbrical muscle using antibo-
dies for MYO9A, synaptophysin and -bungarotoxin. The
use of the distal hind-limb lumbrical muscles for visualiza-
tion of the NMJ allows for whole mount staining and gives
an uninterrupted view of the NMJ (Sleigh et al., 2014). The
pattern of synaptophysin and acetylcholine receptor
(AChR) immunoreactivity was consistent with previous re-
ports (Sleigh et al., 2014), labelling the presynaptic and
postsynaptic regions of the NMJ, respectively
(Wiedenmann and Franke, 1985; Brent and Drapeau,
2002). MYO9A staining co-localized with both markers,
confirming expression of this unconventional myosin at
the NMJ (Fig. 2).
Knockdown of MYO9A in NSC-34
cells affects neurite extension and
branching
To assess whether MYO9A is involved in the morphology
or sprouting of nerve cells, we knocked down MYO9A in
Table 1 The number of variants identified at each stage of the whole exome sequencing analysis workflow for all
patients
Patient Total coding
variants
Total autosomal
recessive variants
Variants following
application of filters
Genes with variants
following manual inspection
Genes with variants
that segregate
1 13 263 1633 26 MYO9A (CHZ)
AKAP11 (CHZ)
TNXB (CHZ)
MYO9A (CHZ)
AKAP11 (CHZ)
2/3 14 065 3265 55 MYO9A (Hom)
MAP3K8 (Hom)
ADAMTSL3 (Hom)
RYR1 (3 CHZ)
ZNF862 (2 Hom)
CSPP1 (Hom)
CHRNB4 (Hom)
ZNF655 (Hom)
TH (CHZ)
DNAH11 (CHZ)
MYO9A (Hom)
MAP3K8 (Hom)
ADAMTSL3 (Hom)
RYR1 (3 CHZ)
ZNF862 (2 Hom)
CSPP1 (Hom)
CHRNB4 (Hom)
ZNF655 (Hom)
Filters applied exclude variants present in41% of the control population (ExAC database) and those that are not predicted to significantly impact protein structure and function (low
and very low impact). Manual inspection includes the analysis of read depth, alignment of reads and quality of variants. The remaining variants are then subject to segregation analysis
with family members. CHZ = compound heterozygous; Hom = homozygous.
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the mouse motor neuron derived cell line, NSC-34, follow-
ing confirmation of MYO9A expression by western blot-
ting (data not shown). Immunofluorescent staining of
NSC-34 cells revealed a punctate staining pattern, with
an accumulation at the growth cone of sprouting neurites,
indicated by actin-rich filopodia stained with phalloidin
(Fig. 3A). Immunofluorescent staining of C2C12 myotubes
revealed no specific staining for MYO9A (data not
shown).
Depletion of MYO9A from NSC-34 cells was confirmed
by qRT-PCR (Fig. 3B), and revealed a significant increase
in the number of primary, secondary and tertiary branches
of the neurons (Fig. 3C and D; 10 fields of view measured
per condition, P5 0.05). The average number of primary
branches increased significantly from 1.27 per cell in con-
trol luciferase knockdowns to 4.82 per cell in MYO9A
knockdowns (P = 0.02, two-sample t-test). Secondary
branching rose from 0.22 per control cell to 7.29 in
MYO9A knockdowns (P = 0.011, two-sample t-test) and
tertiary branching increased from 0 to 2.81 (P = 0.012,
two-sample t-test). There was also a significant increase in
the average length of neurite extensions of 208%
(P5 0.001, two-sample t-test). The average length of neur-
ite extensions from control cells was 55.8mm whereas the
MYO9A knockouts had an average length of 116.1 mm
(Fig. 3D).
Figure 2 MYO9A is expressed at the mouse neuromuscular junction. MYO9A (green) co-localizes with Synaptophysin (blue) and
acetylcholine receptor (AChR) clusters (-bungarotoxin, red) in mouse whole lumbrical muscle mounts. Scale bar = 50 mm.
Figure 3 Knockdown of MYO9A in NSC-34 cells causes increased length and branching of neurites. (A) MYO9A (red) co-localizes
with F-actin (phalloidin, green) at the growth cones of mouse derived NSC-34 cells. (B) Relative expression ratio of quantitative RT-PCR showing
the expression of Myo9a mRNA in control cells and in MYO9A shRNA-mediated knockdown cells (NSC-34). A 6.4-fold decrease in Myo9a
expression is observed. (C) Number of primary, secondary and tertiary branches of control and MYO9A knockdown cells (two-sample t-test,
*P5 0.05). Graph depicts mean  standard error of the mean (SEM). (D) Knockdown of MYO9A in NSC-34 cells leads to aberrant neurite length
and branching as compared to control cells. Scale bar = 100 mm.
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Knockdown of MYO9A in zebrafish
affects tail morphology and causes
abnormal movement
Two MYO9A orthologues were identified in zebrafish,
myo9aa and myo9ab, as shown in Supplementary Fig. 2,
and knockdown was confirmed by reverse transcriptase
PCR (Fig. 4A). The same phenotype, characterized by
curly tails and abnormal swimming in response to tactile
stimulation, was seen in both myo9aa and myo9ab mor-
phants but not in non-injected, control morpholino injected
or p53 morpholino oligonucleotide injected embryos
(Supplementary Fig. 3) (Robu et al., 2007). The morpho-
lino oligonucleotides were then co-injected, along with the
p53 morpholino oligonucleotide to help reduce non-specific
effects. The myo9aa/myo9ab morphants displayed a pro-
nounced phenotype at 48 hpf following dechorionation,
including varying severities of tail curvature (Fig. 4B), ab-
normal swimming and cardiac oedema, which was not alle-
viated by the p53 morpholino oligonucleotide.
At 17 hpf the embryos perform slow alternating move-
ments spontaneously in the chorion, encompassing the first
stage of locomotor development in the zebrafish (Saint-
Amant and Drapeau, 1998). Morphants moved signifi-
cantly less within 10 s than non-injected embryos
(P = 0.025, two-sample t-test), with morphants twisting
their tails only 0.5 times on average as opposed to the
0.95 times performed by control fish (20 embryos observed
from each condition, Supplementary Videos 1–8). The
normal response of zebrafish at 48 hpf to tactile stimulation
is to swim rapidly away by at least one body length (Saint-
Amant and Drapeau, 1998). However, myo9aa/myo9ab
knockdowns in some cases did not respond at all, and in
others were only able to twitch or swim in circles
(Supplementary Videos 9 and 10).
To determine whether the abnormalities observed in the
morphant zebrafish in response to tactile stimulation were
due to a sensory or CNS defect, rather than faulty NMJ
transmission, islet-1 transgenic zebrafish were also injected
with the myo9aa/ab/p53 morpholino oligonucleotides.
Downregulation of both orthologues revealed no changes
to the cranial motor neurons (Supplementary Fig. 4A and
B) or the Rohon Beard primitive sensory cells (Nu¨sslein-
Volhard and Dahm, 2002), suggesting that a lack of
Figure 4 Knockdown of MYO9A in zebrafish. (A) RT-PCR confirming knockdown success of myo9aa and myo9ab in zebrafish injected with
morpholino oligonucleotide. There is loss of the myo9aa transcript and an alternatively spliced myo9ab transcript produced due to intron
retention. Bands from the same gel have been cropped and put together for comparison, demarcated by the white lines. (B) Images of non-
injected and mild/moderate myo9aa/ab morpholino oligonucleotide-injected zebrafish (48 hpf), with the latter displaying varying severities of tail
curvature. Scale bar = 100 mm.
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sensory transmission is not the cause of the abnormal
movement observed.
MYO9A knockdown affects motor
neuron guidance in zebrafish
The formation of the neuromuscular junction in zebrafish
begins with the distribution of pre-patterned AChR clusters
(Flanagan-Steet et al., 2005) followed by the outgrowth of
primary motor neurons. The contact of a motor neuron
causes the integration and stabilization of the aneural
AChR clusters to form NMJs. There is usually a tight
juxtaposition of the presynaptic and postsynaptic regions,
as evidenced by staining of presynaptic proteins such as
synaptic vesicle protein 2 (SV2, encoded by SV2A)
(Buckley and Kelly 1985) and -bungarotoxin, which spe-
cifically labels the postsynaptic AChRs (Brent and Drapeau
2002). In myo9aa/ab morphants, axons are aberrant, either
shortened or over-extended, with some axons appearing to
branch to the adjacent myotome (Fig. 5).
Discussion
Our data provide support for a novel CMS gene: MYO9A,
identified by whole-exome sequencing in two unrelated
families. Diagnosis of CMS can often be problematic as it
manifests with a broad spectrum of symptoms and subtypes
of CMS are difficult to differentiate only on clinical
grounds often requiring genetic testing either by Sanger
sequencing or more recently through whole-exome sequen-
cing (Chae et al., 2015). Whole-exome sequencing has also
proven to be a successful method in the identification of
novel CMS-causing genes that are not obviously associated
with NMJ function, such as the ubiquitously expressed
glycosylation pathway proteins DPAGT (DPAGT1) and
GMPPB (Belaya et al., 2012, 2015).
The variants identified in this study highlight a new
avenue of proteins that may be involved in the NMJ func-
tion, the unconventional myosins. A recent publication has
identified MYO9A mutations in a patient presenting with
arthrogryposis (Bayram et al., 2016). Overlapping pheno-
types and association to the same causative genes have been
described previously for arthrogryposis and CMS, with
joint contractures (arthrogryposis) developing due to
reduced foetal movements based on antenatal neuromuscu-
lar transmission defects (Vajsar et al., 1995; Brownlow
et al., 2001). The prevalence of p.R2283H at 0.2%, with
a predicted homozygote frequency of 4 in 1 000 000 is
higher than might be expected in CMS. We hypothesize
that p.R2283H has a relatively mild effect on protein struc-
ture, with subclinical manifestations when found in homo-
zygosis; however, it has sufficient effect on the protein to
cause disease when coupled with the rarer p.R1517H that
affects a coiled coil region of MYO9A. Interestingly, the
MYO9A mutation described by Bayram et al. (2016) re-
sults in p.G2282E, affecting the neighbouring residue of
our p.R2283H variant. The possibility remains that
p.D1698G could be a population-enriched variant; how-
ever, due to the lack of any large Kurdish control cohorts
the carrier frequency of this variant is difficult to assess.
The findings presented from both in vitro and in vivo
investigations provide support for the presence of
MYO9A at the NMJ. However, the exact location of
MYO9A at the human NMJ has not been determined
and conclusive evidence for the presynaptic nature of the
CMS in our patients has not been obtained. Our mouse
muscle immunofluorescence data demonstrate, however, a
co-localization of MYO9A with the NMJ in muscle whole
mounts. There is also an enrichment of MYO9A at the
growth cones of NSC-34 cells, suggesting MYO9A may
have presynaptic involvement. Other unconventional my-
osins with a similar structure to MYO9A, such as
Figure 5 Motor axons of morphant zebrafish are shortened and abnormally branched. Neuromuscular junctions in absence of
Myo9aa/ab. Non-injected and myo9aa/ab morpholino oligonucleotide-injected embryos were stained for presynaptic motor axons (SV2, green)
and postsynaptic AChRs (-bungarotoxin, red) at 48 hpf. Morphant zebrafish display shortened (arrow) and abnormally branched motor axons,
with some innervating adjacent myotomes (arrowhead). Scale bar = 100 mm.
2150 | BRAIN 2016: 139; 2143–2153 E. O’Connor et al.
 by guest on N
ovem
ber 9, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
MYO10 and MYO5, have also been associated with the
growth cones of neurons (Suter et al., 2000; Yu et al.,
2015). MYO5, like MYO9A, is present in the cell body,
neurites and growth cones of neuronal cells (Suter et al.,
2000) and has been implicated in actin-based organelle
transport in growth cones (Huang et al., 1999). MYO10
is involved in filopodia extension and cell motility, with
deficiency in MYO10 leading to excessive extension of
neurites (Yu et al., 2015). To determine whether MYO9A
is actively involved in the growth cone dynamics we ana-
lysed MYO9A knockdown NSC-34 cells. This similarly re-
vealed an increase in branch count and length of sprouting
neurites. This change in morphology observed in the motor
neuron cell line was also reflected in the zebrafish mor-
phants, in which axon guidance and branching was dis-
rupted and some axons extended beyond their target to
innervate adjacent myotomes.
In the mouse model (Thelen et al., 2015), loss of
MYO9A in the kidney led to a dysregulation of endocyto-
sis, a process crucial for the uptake of activated growth
signal receptors in migrating neurons. Defects in endocyto-
sis may prevent an appropriate response of motor neurons
to guidance cues, an outcome potentially observed in
Myo9aa/ab deficient zebrafish. This cellular function is
also important for synaptic recycling at the NMJ, and fail-
ings here may prevent efficient repackaging of acetylcholine
into vesicles for release (Ceccarelli et al., 1973). Delay in
acetylcholine release is also affected in patients with choline
acetyltransferase CMS, who present with a similar pheno-
type to our patients (Ohno et al., 2001).
Zebrafish NMJs are extremely useful model systems
(Babin et al., 2014), as they are highly homologous to
the mammalian NMJ and development begins when the
embryo is transparent and can be easily manipulated.
Our zebrafish data indicate that Myo9aa/ab are required
for the formation of appropriate non-focal and focal in-
nervations as the presynaptic motor neurons of the mor-
phant fish fail to form typical contacts across the myotome.
The morphological changes observed are reflected function-
ally, with a lack of Myo9aa/ab affecting both the spontan-
eous movement and response to tactile stimulation stages of
locomotor development, suggestive of an NMJ transmission
defect. If morpholino oligonucleotide knockdown caused
developmental delay, shortening of axons at the caudal
end of the tail would be expected; however, motor axons
in the morphant fish were affected throughout the tail sug-
gesting loss of Myo9aa/ab did not simply slow develop-
ment. Presence of a peripheral motor defect was
reaffirmed by the assessment of islet-1 fish and intriguingly
the MYO9A knockout mouse also revealed movement
abnormalities of a hopping and trembling gait
(Abouhamed et al., 2009), with abnormal gait also being
a feature in other mouse models of CMS such as those
affected by MuSK mutations, as well as in mice with pre-
synaptic motor defects (Chevessier et al., 2008; Dale et al.,
2012). The Myo9a null mice also have hydrocephalus,
whereas brain abnormalities were not present in the
zebrafish, the Myo9a heterozygous knockout mice
(Abouhamed et al., 2009) or our patients. However, the
missense variants identified here and the gene knockdown
in zebrafish do not represent a full knockout situation as
seen in the homozygous knockout mice, but rather hypo-
morphic alleles that may provide sufficient MYO9A func-
tion to rescue any brain abnormalities.
We conclude that the unconventional myosin MYO9A is
expressed and functional at the mammalian NMJ, and re-
cessive missense variants of the MYO9A gene are asso-
ciated with CMS in two families. While not fully
conclusive of presynaptic form of CMS, the phenotype of
the patients, such as the severe neonatal onset with respira-
tory distress and bulbar involvement, and the experimental
data obtained in different models are consistent with a pre-
synaptic defect (Palace and Beeson, 2008; Eymard et al.,
2013). There are relatively few forms of presynaptic CMS
that have been described to date (Ohno et al., 2001;
Chaouch et al., 2014; Herrmann et al., 2014), and no mu-
tations in genes encoding proteins that affect the structure
of the presynaptic NMJ have been described. Our data re-
garding the function of MYO9A in vitro and in vivo, how-
ever, suggest a potential role in the structural integrity of
the peripheral nerve terminal.
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